Skip to main content

Table 1 ADEPT baseline demographics and disease severity characteristics

From: Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT

Characteristic Placebo (n = 152) Adalimumab 40 mg every other week (n = 144)
Age (years)a 49.4 ± 11.1 47.8 ± 11.9
Male (%) 55.3 56.3
White (%) 94.1 97.2
Body weight (kg)a 85.4 ± 16.4 86.1 ± 20.5
Psoriatic arthritis duration (years)a 9.3 ± 8.8 9.9 ± 8.3
Psoriasis duration (years)a 16.8 ±12.4 17.2 ± 12.1
Modified total Sharp score (0.5 (%)b 16.4 11.8
Modified total Sharp scorea 20.0 ± 36.3 22.3 ± 46.6
Joint erosion score 10.5 ± 20.2 11.4 ± 25.9
Joint space narrowing score 9.5 ± 17.3 10.9 ± 21.8
CRP (0.287 mg/dl (%)c 22.4 19.4
CRP (mg/dl)a 1.4 ± 1.7 1.4 ± 2.1
Rheumatoid factor-negative (%) 90.1 89.6
Patients taking methotrexate at baseline (%) 51.3 51.4
Tender joint count (0 to 78 joints)a 25.8 ± 17.9 23.6 ± 17.4
Swollen joint count (0 to 76 joints)a 14.4 ± 11.4 13.6 ± 11.6
HAQ Disability Index (0 to 3)a 1.0 ± 0.7 1.0 ± 0.6
  1. HAQ, Health Assessment Questionnaire. P > 0.2 for all adalimumab vs. placebo. aMean ± standard deviation. bAbsence of radiographic progression, defined as modified total Sharp score ≤0.5. cNormal C-reactive protein (CRP) by high-sensitivity assay, defined as ≤0.287 mg/dl.